| Symbol | CNSP |
|---|---|
| Name | CNS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2100 WEST LOOP SOUTH,SUITE 900, HOUSTON, Texas, 77027, United States |
| Telephone | +1 800 946-9185 |
| Fax | — |
| — | |
| Website | https://www.cnspharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001729427 |
| Description | CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Additional info from NASDAQ: |
CNS Pharmaceuticals CFO, Steve OLoughlin, Highlights Companys Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Read moreNew Form EFFECT - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-26 <b>AccNo:</b> 9999999995-26-001762 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-26 <b>AccNo:</b> 0001683168-26-004304 <b>Size:</b> 129 KB
Read moreCNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Companys Recent Strategic Transformation Progress
Read moreDirector Charles Faith L. 🟢 acquired 7.1K shares of CNS Pharmaceuticals, Inc. (CNSP) at $4.79 Transaction Date: May 18, 2026 | Filing ID: 004145
Read moreNew Form D - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001683168-26-004126 <b>Size:</b> 11 KB
Read moreNew Form S-3 - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001683168-26-004123 <b>Size:</b> 329 KB
Read moreNew Form SCHEDULE 13G/A - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000935836-26-000277 <b>Size:</b> 18 KB
Read moreCNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
Read more(50% Neutral) CNS PHARMACEUTICALS, INC. (CNSP) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | Phase2 | Glioblastoma Multiforme, Adult | Active_Not_Recruiting | 2021-05-18 | 2026-07-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Lomustine | Other | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |
| Berubicin | Other | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |
| Placebo | DRUG | Phase PHASE3 | Clear Cell Renal Carcinoma | TERMINATED | NCT01599754 |
| Axitinib | DRUG | Phase PHASE3 | Clear Cell Renal Carcinoma | TERMINATED | NCT01599754 |
| abituzumab | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | WITHDRAWN | NCT03688230 |
| Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 1000 mg or Placebo | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 300 mg or Placebo | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 100 mg or Placebo | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bortezomib | DRUG | Phase PHASE1 | Neuroblastoma Recurrent | COMPLETED | NCT02139397 |
| Bentracimab (PB2452) Infusion | DRUG | Phase PHASE3 | Hemorrhage | COMPLETED | NCT04286438 |
| Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| Ticagrelor Oral Tablet - Pre-Treatment | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| Placebo - Sodium Chloride | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| PB2452 Infusion | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| eflornithine HCl | DRUG | Preclinical | Neuroblastoma | AVAILABLE | NCT03581240 |
| DFMO | DRUG | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT02395666 |
| vorinostat | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| sorafenib | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| dasatinib | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| Ceritinib | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| Lomustine | DRUG | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |
| Berubicin | DRUG | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |